Allianz Asset Management GmbH Buys Shares of 192,160 Ginkgo Bioworks Holdings, Inc. $DNA

Allianz Asset Management GmbH purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 192,160 shares of the company’s stock, valued at approximately $2,802,000. Allianz Asset Management GmbH owned 0.32% of Ginkgo Bioworks as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Shay Capital LLC increased its stake in Ginkgo Bioworks by 6.2% during the second quarter. Shay Capital LLC now owns 19,382 shares of the company’s stock worth $218,000 after purchasing an additional 1,124 shares during the period. California State Teachers Retirement System lifted its holdings in Ginkgo Bioworks by 10.0% during the 2nd quarter. California State Teachers Retirement System now owns 26,674 shares of the company’s stock worth $300,000 after buying an additional 2,426 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Ginkgo Bioworks in the 2nd quarter valued at approximately $29,000. Strs Ohio acquired a new position in shares of Ginkgo Bioworks in the third quarter worth $44,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in shares of Ginkgo Bioworks during the second quarter worth $45,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DNA shares. Wall Street Zen cut Ginkgo Bioworks from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, January 21st. Finally, TD Cowen reduced their target price on shares of Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $10.50.

Ginkgo Bioworks Trading Up 1.7%

Shares of Ginkgo Bioworks stock opened at $9.39 on Thursday. The stock has a market capitalization of $568.88 million, a P/E ratio of -1.51 and a beta of 1.55. The business’s fifty day moving average price is $9.14 and its 200 day moving average price is $10.90. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $17.58.

Ginkgo Bioworks Profile

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.